Search for a command to run...
Purpose: to fi nd the duration of hypolipidemic effect after the course of intravenous laser therapy in patients with coronary artery disease (CAD) and lipid metabolism disorders resistant to hypolipidemic pharmacotherapy. Patients and methods. 40 patients with CAD and lipid metabolism disorders (LMD) resistant to hypolipidemic drugs were enrolled in the trial. Patients were divided into two comparable groups depending on the curative technique: 20 patients from Group 1 (main group) had intravenous laser blood irradiation (ILBI) and supportive medicamentous therapy (SMT). 20 patients from Group 2 (control group) had only SMT. Results and discussion. Initially, patients in both groups had LMD signs despite of hypolipidemic drug therapy: elevated levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), atherogenic index (AI), and reduced high-density lipoprotein cholesterol (HDL-C) compared to normal values. Baseline values in both groups were statistically insignifi cant for TC, HDL-C, LDL-C and AI levels which indicated comparability between the groups. The study results demonstrated that patients in the main lasered group with ILBI course demonstrated much better hypolipidemic effect in 1 and 3 months after the treatment compared to baseline values: signifi cant reduction in TC by 19.1 % and 16.1 %, respectively; signifi cant reduction in LDL-C by 24.1 % and 21.8 %, respectively; signifi cant reduction in AI by 33.7 % and 29.1 %, respectively. Four months after the ILBI course, hypolipidemic effect became signifi cantly less evident, and lipid profi le indicators in the main group returned to baseline levels, except for total cholesterol. Therefore, in 4 months after ILBI course, patients require a repeated laser therapy course. The controls throughout the observation period had no signifi cant positive dynamics compared to baseline values. Conclusion . In patients with CAD and LMD resistant to hypolipidemic drugs, ILBI therapy corrects LMD. It has been demonstrated by the signifi cant reduction in TC, LDL-C, and AI levels, as well as by increased HDL-C level, although lipid profi le parameters did not reach their normal or target values. The obtained positive effect persisted for 3 months after the course of laser therapy. After that, ILBI positive effect gradually went down, except the total cholesterol. That is why, in four months patients require a repeat course of laser therapy. To achieve a full hypolipidemic effect in this category of patient, it is necessary to develop and incorporate other non-drug curative techniques.